TA
TARX
Tarsier Pharma Ltd.
No data for this timeframe.
Vol
SEC Reports2
CIK 0002102720
Recent Activity
Jun 8, 2026
SEC
Tarsier Pharma, an Israeli late clinical-stage biopharmaceutical company focused on inflammatory ocular diseases, files
F-1/A — Impact 5/10
May 18, 2026
SEC
Tarsier Pharma Ltd., an Israeli late clinical-stage biopharmaceutical company focused on inflammatory ocular diseases, f
F-1/A — Impact 5/10
Latest Reports
NEUTRAL
F-1/A
5/10
Tarsier Pharma, an Israeli late clinical-stage biopharmaceutical company focused on inflammatory ocular diseases, files
Jun 8, 2026
NEUTRAL
F-1/A
5/10
Tarsier Pharma Ltd., an Israeli late clinical-stage biopharmaceutical company focused on inflammatory ocular diseases, f
May 18, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 5.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
No analyst rating data available yet. Consensus ratings and individual firm actions are collected periodically from financial data providers.
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 21, 2026
Clinical Trial
A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma
Phase Phase 3 — COMPLETED